Get the Stockscreener App
18.59
1.90%
-0.36
After Hours:
17.93
-0.66
-3.55%
Anaptysbio Inc stock is traded at $18.59, with a volume of 633.07K.
It is down -1.90% in the last 24 hours and up +10.52% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$18.95
Open:
$18.17
24h Volume:
633.07K
Relative Volume:
0.66
Market Cap:
$576.23M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.0576
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-0.64%
1M Performance:
+10.52%
6M Performance:
-44.51%
1Y Performance:
-17.45%
1-Day Range:
$17.83
$18.80
1-Week Range:
$17.50
$19.60
52-Week Range:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
18.59 | 576.23M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio (NASDAQ:ANAB) Trading Up 2.5%What's Next? - MarketBeat
How to Take Advantage of moves in (ANAB) - news.stocktradersdaily.com
AnaptysBio (NASDAQ:ANAB) Shares Gap UpShould You Buy? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 5,733 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Trading Down 4.1%Should You Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) to Repurchase $75.00 million in Stock - MarketBeat
Leerink Partners Sticks to Their Buy Rating for AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? - MSN
AnaptysBio (NASDAQ:ANAB) to Repurchase $75.00 million in Shares - Defense World
AnaptysBio Shares Jump on Buyback Program Authorization - MarketWatch
Crude Oil Gains 1%; US Composite PMI Surges In March - Benzinga
Anaptys Announces Stock Repurchase Plan - GlobeNewswire
AnaptysBio authorizes $75 million stock buyback plan By Investing.com - Investing.com South Africa
Anaptys announces $75 million stock repurchase plan - MSN
AnaptysBio Announces $75 Mln Stock Repurchase Plan - Nasdaq
AnaptysBio stock rises following stock repurchase plan By Investing.com - Investing.com Canada
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday - Benzinga
AnaptysBio Approves $75 Million Buyback Plan; Shares Rise -March 24, 2025 at 09:50 am EDT - Marketscreener.com
AnaptysBio authorizes $75 million stock buyback plan - Investing.com India
AnaptysBio, Inc. Authorizes $75 Million Stock Repurchase Plan - Nasdaq
AnaptysBio (NASDAQ:ANAB) Stock Price Up 4.4%What's Next? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
AlphaQuest LLC Purchases 4,237 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Position Raised by Victory Capital Management Inc. - MarketBeat
Victory Capital Management Inc. Purchases 97,200 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Markets Insider
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 - MarketBeat
Rhumbline Advisers Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
When (ANAB) Moves Investors should Listen - Stock Traders Daily
Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
AnaptysBio (ANAB) to Release Quarterly Earnings on Monday - MarketBeat
AnaptysBio: A Shadow Of Its Former Self (NASDAQ:ANAB) - Seeking Alpha
Palmoplantar Pustulosis Clinical and Non-Clinical Studies, - openPR
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at HC Wainwright - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - MarketBeat
H.C. Wainwright maintains AnaptysBio stock Neutral with $22 target By Investing.com - Investing.com Canada
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):